Statin treatment for patients with heart failure

Nature Reviews Cardiology

Volumn 7, Issue 5, 2010, Pages 249-255

  Tang, W H Wilson ^a   Francis, Gary S ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MORTALITY; MYOSITIS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SYSTOLIC HEART FAILURE;

COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77951764745     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.29     Document Type: Review

References (49)

1. Lipinski, M. J., Abbate, A., Fuster, V. & Vetrovec, G. W. Drug insight: statins for nonischemic heart failure-evidence and potential mechanisms. Nat. Clin. Pract. Cardiovasc. Med. 4, 196-205 (2007).
2. Ramasubbu, K., Estep, J., White, D. L., Deswal, A. & Mann, D. L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 51, 415-426 (2008).
3. Francis, S. E., Holden, H., Holt, C. M. & Duff, G. W. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J. Mol. Cell. Cardiol. 30, 215-223 (1998).
4. Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990).
5. Torre-Amione, G. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27, 1201-1206 (1996).
6. Chung, H. K. et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med. 34, 451-461 (2002).
7. Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402 (2000).
8. Mozaffarian, D., Nye, R. & Levy, W. C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol. 93, 1124-1129 (2004).
9. Sola, S. et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J. Card. Fail. 11, 607-612 (2005).
10. Tousoulis, D. et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur. J. Heart Fail. 7, 1126-1132 (2005).
11. Bleske, B. E. et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J. Am. Coll. Cardiol. 47, 338-341 (2006).
12. Krum, H. et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Fail. 13, 1-7 (2007).
13. Hanada, T. & Yoshimura, A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13, 413-421 (2002).
14. Brown, J. H., Del Re, D. P. & Sussman, M. A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. 98, 730-742 (2006).
15. Drexler, H. et al. Endothelial function in congestive heart failure. Am. Heart J. 126, 761-764 (1993).
16. Diodati, J. G., Dakak, N., Gilligan, D. M. & Quyyumi, A. A. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98, 17-24 (1998).
17. Bates, K., Ruggeroli, C. E., Goldman, S. & Gaballa, M. A. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 283, H768-H775 (2002).
18. Trochu, J. N. et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc. Res. 60, 250-258 (2003).
19. Walter, D. H. et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrowderived endothelial progenitor cells. Circulation 105, 3017-3024 (2002).
20. Kjekshus, J., Pedersen, T. R., Olsson, A. G., Faergeman, O. & Pyörälä, K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. 3, 249-254 (1997). (Pubitemid 127674856)
21. Horwich, T. B., Hamilton, M. A., Maclellan, W. R. & Fonarow, G. C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail. 8, 216-224 (2002).
22. Horwich, T. B., Hernandez, A. F., Dai, D., Yancy, C. W. & Fonarow, G. C. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am. Heart J. 156, 1170-1176 (2008).
23. Rauchhaus, M. et al. The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 1933-1940 (2003). (Pubitemid 37485568)
24. von Haehling, S., Schefold, J. C., Springer, J. & Anker, S. D. The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. Heart Fail. Clin. 4, 141-151 (2008).
25. Emberson, J. R. et al. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol. 49, 311-319 (2007).
26. Horwich, T. B., MacLellan, W. R. & Fonarow, G. C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. 43, 642-648 (2004).
27. Ray, J. G., Gong, Y., Sykora, K. & Tu, J. V. Statin use and survival outcomes in elderly patients with heart failure. Arch. Intern. Med. 165, 62-67 (2005).
28. Anker, S. D. et al. Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int. J. Cardiol. 112, 234-242 (2006).
29. Foody, J. M. et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092 (2006).
30. Go, A. S., Lee, W. Y., Yang, J., Lo, J. C. & Gurwitz, J. H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296, 2105-2111 (2006).
31. Krum, H. et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int. J. Cardiol. 119, 48-53 (2007).
32. Krum, H. et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology 108, 28-34 (2007).
33. Huan Loh, P. et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am. Heart J. 153, 537-544 (2007).
34. Ryan, R. P., McManus, R. J., Mant, J., Macleod, J. A. & Hobbs, F. D. Statins in heart failure: Retrospective cohort study using routine primary care data. Ann. Med. 41, 490-496 (2009).
35. Khush, K. K. et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115, 576-583 (2007).
36. Ouzounian, M. et al. Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J. Card. Fail. 15, 241-248 (2009).
37. Shah, R., Wang, Y. & Foody, J. M. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. Am. J. Cardiol. 101, 217-222 (2008).
38. Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007).
39. Tavazzi, L. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239 (2008).
40. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19, 117-125 (2005).
41. Rawlings, R. et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am. J. Cardiol. 103, 437-441 (2009).
42. Tsutamoto, T. et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur. J. Heart Fail. 11, 1195-1201 (2009).
43. Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
44. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
45. Cleland, J. G., Squire, I. & Ng, L. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study. J. Am. Coll. Cardiol. 52, 1104-1105 (2008).
46. Cleland, J. G. et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J. Am. Coll. Cardiol. 54, 1850-1859 (2009).
47. McMurray, J. J. et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120, 2188-2196 (2009).
48. Folkeringa, R. J. et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J. Card. Fail. 12, 134-138 (2006).
49. Dickinson, M. G. et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am. Heart J. 153, 573-578 (2007).